News and controversy in inflammatory bowel disease treatment

Submitted: 29 April 2013
Accepted: 29 April 2013
Published: 30 April 2013
Abstract Views: 859
PDF: 1199
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Background: The treatment of Inflammatory bowel disease comes from many years of esperience, clinical trials and mistakes.
Discussion: In patients with active Crohn disease steroids are considerated the first choice, but recently, the introduction of anti-TNF alfa agents (infliximab and adalimumab) has changed the protocols. Anti-TNF are also used for closing fistula after surgical curettage. An efficently preventive treatment of Crohn disease still has not been found but hight dose of oral salicylates, azatioprine or 6-MP and antibiotics might be useful. In severe attacks of ulcerative colitis, high dose iv treatment of steroids are required for a few days. Later on, a further treatment with anti- TNF might delay the need of surgery. In patients with mild to moderate attacks of ulcerative colitis, topical treatment is preferred, it consists of enemas, suppositories or foams containing 5-aminosalycilic acid, traditional steroids, topical active steroids. Topical treatment can be associated with oral steroids or oral salicylates. Oral salicylates or azatioprine are used for prevention of relaps.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Straforini, G., Brugnera, R., Tambasco, R., Rizzello, F., Gionchetti, P., & Campieri, M. (2013). News and controversy in inflammatory bowel disease treatment. Italian Journal of Medicine, 3(3), 179–186. https://doi.org/10.4081/itjm.2009.179